These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 30941606)

  • 1. Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.
    Shirley M
    Drugs; 2019 May; 79(7):791. PubMed ID: 30941606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Case of Single-lung Transplant in a Patient with Mycobacterium avium Pulmonary Disease Successfully Treated with Amikacin Liposome Inhalation Suspension.
    Ozeki T; Higo H; Omori H; Mori S; Tanaka S; Makimoto G; Ninomiya K; Taniguchi A; Fujii M; Miyoshi K; Rai K; Ichihara E; Ohashi K; Sugimoto S; Hotta K; Tabata M; Toyooka S; Maeda Y; Miyahara N
    Intern Med; 2024 Sep; ():. PubMed ID: 39261070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use.
    Hoy SM
    Clin Drug Investig; 2021 Jun; 41(6):591. PubMed ID: 33880719
    [No Abstract]   [Full Text] [Related]  

  • 4. Amikacin liposome inhalation suspension clinical benefit-risk assessment for refractory
    Marras TK; Hassan M; Mange KC; Ciesielska M; Murthy SD; Jumadilova Z; Chatterjee A
    ERJ Open Res; 2022 Jul; 8(3):. PubMed ID: 35821755
    [No Abstract]   [Full Text] [Related]  

  • 5. ALIS (Amikacin Liposome Inhalation Suspension): The Beginning of a Wonderland?
    Daley CL; Olivier KN
    Am J Respir Crit Care Med; 2018 Dec; 198(12):1473-1475. PubMed ID: 30365392
    [No Abstract]   [Full Text] [Related]  

  • 6. Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory
    Hashimoto K; Nii T; Sumitani H; Yokoyama M; Miyamoto S; Mihashi Y; Nagata Y; Matsuki T; Tsujino K; Miki K; Kida H
    Infect Drug Resist; 2023; 16():6629-6634. PubMed ID: 37840829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey.
    Swenson C; Lapinel NC; Ali J
    Open Forum Infect Dis; 2020 Apr; 7(4):ofaa079. PubMed ID: 32322600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Outcomes of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Pulmonary Disease.
    Kim BG; Kim SR; Jhun BW
    Tuberc Respir Dis (Seoul); 2024 Apr; 87(2):202-205. PubMed ID: 37726944
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of disseminated Mycobacterium avium complex infection of beige mice with liposome-encapsulated aminoglycosides.
    Bermudez LE; Yau-Young AO; Lin JP; Cogger J; Young LS
    J Infect Dis; 1990 Jun; 161(6):1262-8. PubMed ID: 2345306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation Suspension.
    Ali J; Wu J; Hassan M; Tsai JH; Touba N; McCarrier K; Ballard M; Chatterjee A
    Pulm Ther; 2024 Sep; 10(3):315-330. PubMed ID: 39012432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical Approval Update.
    Kaufman MB
    P T; 2019 Jan; 44(2):42-44. PubMed ID: 30766008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laryngitis after inhalation of liposomal amikacin.
    Morita A; Namkoong H; Hosoya M; Hasegawa N
    Clin Case Rep; 2022 Feb; 10(2):e05350. PubMed ID: 35369384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series.
    Davis KK; Kao PN; Jacobs SS; Ruoss SJ
    BMC Pulm Med; 2007 Feb; 7():2. PubMed ID: 17319962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases.
    Yagi K; Ishii M; Namkoong H; Asami T; Iketani O; Asakura T; Suzuki S; Sugiura H; Yamada Y; Nishimura T; Fujiwara H; Funatsu Y; Uwamino Y; Kamo T; Tasaka S; Betsuyaku T; Hasegawa N
    BMC Infect Dis; 2017 Aug; 17(1):558. PubMed ID: 28793869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin.
    Bermudez LE; Wu M; Young LS
    J Infect Dis; 1987 Sep; 156(3):510-3. PubMed ID: 3611835
    [No Abstract]   [Full Text] [Related]  

  • 16. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin.
    Ferro BE; Meletiadis J; Wattenberg M; de Jong A; van Soolingen D; Mouton JW; van Ingen J
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1097-105. PubMed ID: 26643335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of activities of amikacin and sulphamethoxazole against Mycobacterium avium-intracellulare.
    Yew WW; Tam CM; Chan CY; Li MS; Cheng AF
    Int J Clin Pharmacol Res; 1993; 13(2):65-8. PubMed ID: 8354590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postantibiotic effect of amikacin and rifapentine against Mycobacterium avium complex.
    Bermudez LE; Wu M; Young LS; Inderlied CB
    J Infect Dis; 1992 Oct; 166(4):923-6. PubMed ID: 1445599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model.
    Petersen EA; Grayson JB; Hersh EM; Dorr RT; Chiang SM; Oka M; Proffitt RT
    J Antimicrob Chemother; 1996 Nov; 38(5):819-28. PubMed ID: 8961051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease.
    Rubino CM; Onufrak NJ; van Ingen J; Griffith DE; Bhavnani SM; Yuen DW; Mange KC; Winthrop KL
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):573-574. PubMed ID: 33871806
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.